MLN2238,
Ixazomib,
1072833-77-2,
MLN2238,
MLN-2238,
MLN 2238,
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid,
(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid,
Ixazomib (MLN2238),
UNII-71050168A2,
CHEMBL2141296,
71050168A2,
Ixazomib [INN],
Ixazomib [USAN:INN],
Ixozamib,
Ixazomib Impurity,
Ixazomib (USAN),
Ixazomib(MLN2238),
MLN2238(Ixazomib),
C14H19BCl2N2O4,
GTPL8450,
SCHEMBL3742758,
CHEBI:90942,
CTK4A5116,
KS-00000PQX,
EX-A547,
BCP02410,
BCP24078,
ABP000732,
BDBM50398609,
MFCD18251438,
s2180,
AKOS015995120,
ZINC169946773,
BCP9000953,
CS-1657,
DB09570,
RL00318,
SB19501,
Boronic acid, b-((1R)-1-((2-((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl)-,
NCGC00249611-01,
NCGC00249611-03,
AC-28456,
AT-42310,
BC659994,
HY-10453,
SC-94531,
AB0033791,
FT-0660371,
SW219743-1,
X7547,
J3.602.191H,
D10130,
MLN2238,MLN 2238,MLN-2238/,
S-7673,
J-001749,
BRD-K78659596-001-01-3,
1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid,
N-[(1R)-1-borono-3-methylbutyl]-N(2)-(2,5-dichlorobenzoyl)glycinamide,
(1R)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutylboronic acid,
[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methyl-butyl]boronic acid,
[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid,
[(1R)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid,
MLN-2238|||[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid,
NINLARO,
Ixazomib citrate,
D01MML,
cc-437,
MLN9708,
Ixazomib, 98% - 1G 1g,
ACN-043692,
A4008,
A10600,
B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid,
[(1~{r})-1-[2-[[2,5-Bis(Chloranyl)phenyl]carbonylamino]ethanoylamino]-3-Methyl-Butyl]boronic Acid,